Therapy Areas: Oncology
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial
11 May 2026 - Chinese biopharmaceutical company Harbour BioMed (HKEX:02142) announced on Friday that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) applicatio...
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
11 May 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administrati...
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
...
Halozyme and GSK sign global drug‑delivery collaboration
...
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNP...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel...